These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15291805)

  • 1. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.
    Valent P; Ghannadan M; Akin C; Krauth MT; Selzer E; Mayerhofer M; Sperr WR; Arock M; Samorapoompichit P; Horny HP; Metcalfe DD
    Eur J Clin Invest; 2004 Aug; 34 Suppl 2():41-52. PubMed ID: 15291805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIT mutations in mastocytosis and their potential as therapeutic targets.
    Gotlib J
    Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis.
    Ruano I; Gargini R; Izquierdo M
    Br J Haematol; 2010 Jan; 148(1):59-68. PubMed ID: 19804454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
    Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
    Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
    Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
    Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology, classification and treatment of human mastocytosis.
    Valent P
    Wien Klin Wochenschr; 1996; 108(13):385-97. PubMed ID: 8766423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis.
    Sundram UN; Natkunam Y
    J Cutan Pathol; 2007 Apr; 34(4):289-95. PubMed ID: 17381798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.
    Arock M; Valent P
    Expert Rev Hematol; 2010 Aug; 3(4):497-516. PubMed ID: 21083038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis, progression patterns and prognostication in mastocytosis.
    Sperr WR; Valent P
    Expert Rev Hematol; 2012 Jun; 5(3):261-74. PubMed ID: 22780207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic mastocytosis: current classification and novel therapeutic options.
    Barbie DA; Deangelo DJ
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
    Valent P; Sperr WR; Schwartz LB; Horny HP
    J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
    McClintock-Treep SA; Horny HP; Sotlar K; Foucar MK; Reichard KK
    J Clin Pathol; 2009 Dec; 62(12):1147-9. PubMed ID: 19729359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of Kit in disease and the application of pharmacogenetics.
    Akin C; Metcalfe DD
    J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.
    Molderings GJ; Kolck UW; Scheurlen C; Brüss M; Homann J; Von Kügelgen I
    Scand J Gastroenterol; 2007 Sep; 42(9):1045-53. PubMed ID: 17710669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.